Compare INTA & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTA | PHVS |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2021 | 2020 |
| Metric | INTA | PHVS |
|---|---|---|
| Price | $36.25 | $34.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $41.43 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 800.4K | 393.4K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,120,000.00 | N/A |
| Revenue This Year | $15.91 | N/A |
| Revenue Next Year | $13.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.09 | N/A |
| 52 Week Low | $19.01 | $19.56 |
| 52 Week High | $47.93 | $36.60 |
| Indicator | INTA | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.